T3 - Cytomel 100mcg/tab 100 Tabletten by LA Pharma

Usage

1. Establish GH baseline first — begin Growth Hormone injections and allow two full weeks before adding T3 Cytomel, so GH-mediated deiodinase suppression creates the metabolic gap that Liothyronine will fill.
2. Start with a quarter-tablet (25 mcg) scored from the LA Pharma 100 mcg tablet using a clean pill splitter; take in the morning with water, away from calcium-rich food or supplements that impair thyroid-hormone absorption.
3. Advance to 50 mcg (half-tablet) after five to seven days if cardiovascular response — resting heart rate, body temperature — remains within comfortable limits; this dose pairs most commonly with GH at 2–3 IU/day.
4. Consider a further increase to 75 mcg if GH dose exceeds 3–4 IU/day and fat-loss plateau is observed; split this across two daily doses (50 mcg AM + 25 mcg early afternoon) to smooth plasma levels.
5. Maintain the peak dose for the central weeks of your GH protocol, then step dose down symmetrically — reducing by 25 mcg every five to seven days — as the GH phase concludes.
6. Store tablets in the original blister packaging at room temperature, protected from moisture and direct light; the sealed blister format supplied in the 100-tablet pack preserves potency across the full protocol duration.

Warnings

Frequently asked questions

How does Growth Hormone suppress endogenous T3 and why does this matter for fat loss?

GH administration reduces type-1 deiodinase activity in the liver, lowering the peripheral conversion of T4 into active T3. This GH-induced decline in circulating T3 limits the mitochondrial capacity to oxidise the free fatty acids that GH itself mobilises from adipose tissue. Supplementing with exogenous Liothyronine directly restores T3 availability, ensuring that GH-liberated fatty acids are fully combusted rather than partially re-stored.

Is combining exogenous T3 with GH more effective for lipolysis than using GH alone?

Yes — the combination is demonstrably more effective than GH monotherapy. GH drives free-fatty-acid release at the adipocyte level, but oxidising those lipids requires adequate T3 to support mitochondrial beta-oxidation enzyme transcription. Research in clinical hypopituitary populations shows that co-administration of T3 with GH produces greater reductions in fat mass than GH treatment alone, validating the synergy for body-composition-focused protocols.

At what point in a GH protocol should Liothyronine be introduced for maximum lipolytic effect?

Introduce Liothyronine approximately two to three weeks after GH injections begin. This timing allows GH to establish suppression of endogenous T3 production — the physiological window where exogenous T3 adds true replacement value rather than mere supplementation. Starting T3 simultaneously with GH can overshoot replacement needs before the GH-induced deiodinase suppression has fully developed, making staggered introduction the pharmacologically rational approach.

Can LA Pharma T3 Cytomel 100 mcg tablets be split for lower-dose protocols within a GH stack?

The scored tablet design supports splitting into quarters, yielding 25 mcg portions suitable for graduated dosing throughout a GH-based protocol. Splitting should be performed with a clean pill cutter to preserve content uniformity across each fragment. Most GH-augmented fat-loss protocols operate between 25 and 75 mcg of T3 daily, meaning a single 100 mcg tablet covers one to four daily doses depending on the target level.

How many tablets does the 100-tab pack of LA Pharma T3 Cytomel provide relative to a standard GH cycle length?

At a common maintenance dose of 50 mcg per day — one half-tablet — the 100-tablet pack supplies 200 doses, covering approximately 200 days of use at that level. For a structured 10–12 week GH-combination protocol using 50 mcg daily, the pack comfortably covers the full duration with tablets remaining for taper adjustment. Blister packaging preserves tablet integrity and discretion throughout storage and shipping. (2) angle_used

Manufacturer

LA Pharma's supply-chain architecture for its T3 Cytomel 100 mcg tablets is built around cold-chain integrity and anti-counterfeiting traceability: each 100-tablet blister shipment exits the GMP Standard-certified facility carrying a batch-specific identifier that links the physical pack to the corresponding finished-product HPLC dataset generated at release. Distribution partners in the EU, UK, and US are required to maintain ambient temperature-controlled storage — critical for Liothyronine sodium stability across the tablet matrix. LAL endotoxin screening of raw Liothyronine sodium is conducted at goods-in inspection before any material reaches the compression line, providing a documented quality gate that precedes tableting rather than following it.